Search Results
May 22, 2026, 10:15 ET Protein Expression Market worth $7.65 billion by 2031 | MarketsandMarkets™
Rising demand for gene synthesis, protein expression optimization, cell line development, and custom protein production services across research and manufacturing applications further supports the segment's leadership. Additionally, expansion of biologics, biosimilars, and cell and gene therapy pipelines
More news about: MarketsandMarkets
May 22, 2026, 06:00 ET As Genetics Reshapes Healthcare, SCU Prepares Students for Growing Workforce
diagnostics, inherited cancer risk assessment, and genomic tools in research and clinical care.Emerging technologies such as advanced DNA analysis, gene editing, and the use of AI in genetic medicine are rapidly transforming how diseases are detected, understood, and treated. These advances are helping
More news about: Southern California University of Health Sciences
May 22, 2026, 02:47 ET Gene Solutions 於 TJCC 2026 展示 AI 驅動多體學液態切片創新成果: 推動台灣精準腫瘤醫學發展
準腫瘤醫學發展Gene Solutions 於 TJCC 2026 的參與，凸顯 AI 驅動多體學液態切片於台灣精準腫瘤醫學領域中日益重要的臨床價值與發展潛力Gene Solutions 全球醫學事務總監 Ida Deleskog Lindstroem 表示：「台灣擁有高度成熟的癌症醫療體系，臨床醫師對基因檢測具備豐富經驗，並樂於接受具臨床驗證基礎的創新技術。本次參與 TJCC 2026，我們看見臨床醫師正積極探索 AI 驅動多體學液態切片如何協助更早期癌症偵測、更精準的治療決策，以及 ctDNA 的長期精準監測。Gene Solutions 將持續與台灣臨床醫師、醫院、醫學會及產業夥伴深化合作，將更多具實證基礎、可信賴且更容易取得的基因檢測方案帶給更多病人。目前我們已有多項研究計畫持續推進中，並已
More news about: Gene Solutions Genomics Pte., Ltd
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
worldwide. Although immunotherapy has transformed the treatment landscape of NSCLC, therapeutic options are still very limited for patients without driver gene mutations who have failed immunotherapy, with overall survival typically less than 12 months. With longer follow-up, we are encouraged to see outstanding
More news about: Innovent Biologics
May 21, 2026, 18:45 ET What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
drivers of claims above $3 million. Other contributing factors include conditions existing from birth (congenital anomalies), complicated surgeries and gene therapies.
More news about: Sun Life U.S.
May 21, 2026, 17:30 ET Rutgers Cancer Institute and RWJBarnabas Health to Highlight Advances Shaping the Future of Cancer Research at the 2026 ASCO Annual Meeting
ABSTRACT 12038: The HERO trial evaluated Tai Chi Qigong (TCQ) for its effects on fatigue-related gene expression profiles compared with an exercise-intensity matched intervention and usual care. Among the 113 participants, TCQ favorably regulated genes
More news about: Rutgers Cancer Institute and RWJBarnabas Health
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
has spread to other parts of your body (metastatic), andhas a certain mutation in the human epidermal growth factor receptor 2 (HER2) geneYour healthcare provider will perform a test to make sure HERNEXEOS is right for you.It is not known if HERNEXEOS is safe and effective
More news about: Boehringer Ingelheim
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
of:Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved testIMPORTANT SAFETY INFORMATION FOR RETEVMO (selpercatinib)Hepatotoxicity: Serious
More news about: Eli Lilly and Company
May 21, 2026, 14:32 ET MGI Tech Showcases Next-Generation Laboratory Automation and Multi-Omics Solutions at SLAS 2026
training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers
More news about: MGI Tech Co., Ltd.
May 21, 2026, 13:23 ET New report highlights gap between New GMO hype and global market reality
(and not 'old genetic engineering' or old GMOs: transgenic GMOs), also commonly referred to as 'New Genomic Techniques' used by EU institutions or 'gene editing', which is commonly used in North America to describe GMOs into which no 'foreign' DNA has been incorporated. About ENGA The
More news about: Non-GMO Project
May 21, 2026, 12:00 ET Genesis AI Expands Executive Team Across Legal and Operations with Former X and Tesla Leaders
recently unveiled innovations, including the industry's most advanced robotic brain, GENE-26.5, and the company's dexterous robotic hand.Kumar brings extensive experience scaling complex robotics and hardware products from early-stage
More news about: Genesis AI
May 21, 2026, 11:21 ET Why a $35 Million Greenland Rare Earth Deal Just Put One Small-Cap on Every Investor's Radar
rebranded the combined company. The result is a unique structure with two divisions: a Natural Resources arm focused on Greenland projects, and a Cell and Gene Therapy arm that retained the KLTO-202 ALS program. [4]Until now, the company's flagship asset was the Skaergaard Project in Southeast
More news about: USA News Group
May 21, 2026, 10:24 ET BioMarin apresenta novos dados sobre o efeito do tratamento de longo prazo com VOXZOGO® (vosoritida) na envergadura dos braços, saúde óssea e crescimento em crianças com acondroplasia no Encontro Anual de 2026 da Sociedade de Endocrinologia Pediátrica
Com incidência de 1 a cada 25 mil nascidos vivos,3 a acondroplasia é uma condição genética grave e progressiva, causada por uma mutação no gene FGFR3.4 Considerada a causa mais comum de nanismo desproporcional, ela causa baixa estatura, com pernas e braços mais curtos que o tronco,
More news about: BioMarin
May 21, 2026, 10:15 ET Cell Isolation Market/Cell Separation Market worth $7.97 billion by 2031 | MarketsandMarkets™
applications. Rising demand for viable, high-purity cell populations in translational research, single-cell analysis, biomarker discovery, and cell and gene therapy manufacturing is accelerating the adoption of magnetic-activated cell sorting, fluorescence-activated cell sorting, density gradient separation,
More news about: MarketsandMarkets
May 21, 2026, 08:30 ET Overcoming Challenges in Viral Vector Manufacturing to Meet Commercial Demand for Gene Therapies, Upcoming Webinar Hosted by Xtalks
insights from case studies.TORONTO, May 21, 2026 /PRNewswire/ -- Gene therapy is reshaping modern medicine, offering the potential for lasting, even curative treatments for a wide range of indications. However, realizing
More news about: Xtalks
May 21, 2026, 08:30 ET Greenland Mines Signs Definitive Agreement to Acquire the Sarfartoq Neodymium-Praseodymium Rare Earths Project in Greenland
the Skaergaard Project in southeast Greenland — one of the largest undeveloped palladium, gold and platinum deposits in the world — and (2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. Through its recent acquisition of Greenland Mines Corp., the Company holds the Skaergaard
More news about: Greenland Mines Ltd
May 21, 2026, 08:00 ET Origin Agritech Announces Financial Results for the First Half of Fiscal Year 2026
China's key corn-growing markets.In November 2025, Origin executed a patent license agreement with Shunfeng BioTech, bringing the Cas-SF01 gene-editing nuclease into the Company's biotechnology toolkit. The license materially strengthens Origin's position in next-generation corn trait development
More news about: Origin Agritech Limited
May 21, 2026, 05:31 ET Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsight
International networks and patient organization partnerships are vital for progress, enabling collaboration and large-scale studies, Javed further added. Gene therapy, Javed said, shows promise but currently faces safety and targeting challenges; PMP22 silencers for CMT1A are close to being tested in patients.Charcot–Marie–Tooth
More news about: DelveInsight Business Research, LLP
May 21, 2026, 05:30 ET Genethon and Ampersand Biomedicines announce partnership to design novel AAV vectors with enhanced tissue specificity for more effective and better tolerated gene therapies
world-class gene therapy expertise with Ampersand's leadership in designing and developing precision biologics, this collaboration aims to develop more finely targeted, safer and more effective AAV-based gene therapies.About GenethonA pioneer in the discovery and development of gene therapies
More news about: Ampersand Biomedicines
May 20, 2026, 16:45 ET Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
College, Oxford.About Duchenne Muscular DystrophyDMD is a rare, progressive neuromuscular disease caused by mutations in the DMD gene, which encodes dystrophin, a protein essential for maintaining muscle-cell structural integrity. Loss of functional dystrophin causes muscle fibers to
More news about: Atossa Therapeutics Inc
May 20, 2026, 11:11 ET Functional Unemployment Edges Higher Amid Signs of Labor Market Weakness, Says Ludwig Institute
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity
May 20, 2026, 10:34 ET /C O R R E C T I O N -- InMed Pharmaceuticals/
polypeptide) monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a potentially first-in-class anti-CGRP (calcitonin gene-related peptide) and anti-PACAP bispecific antibody with Phase 1 healthy volunteer data expected in 2027. Together, MT-001 and MT-002 target validated,
More news about: InMed Pharmaceuticals
May 20, 2026, 10:15 ET High Throughput Screening Market worth $45.90 billion by 2031 | MarketsandMarkets™
due to increasing drug discovery activity, rising pharmaceutical and biotechnology R&D spending, and the growing need to screen large compound, gene, and cell libraries more efficiently. HTS platforms are now widely used in early-stage discovery to identify promising hits, validate targets, and reduce
More news about: MarketsandMarkets
May 20, 2026, 09:50 ET Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
regenerate damaged tissue and improve cognitive and physical function later in life. Many of these cell-based approaches are now being combined with gene therapies, immune-focused treatments, and personalized medicine strategies to create more targeted solutions. Industry
More news about: Market News Updates
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
/ β-catenin pathway-dependent gene expression. Since E7386 is thought to act on the CBP / β-catenin transcription complex located at the most downstream of the Wnt signaling, it is expected to inhibit not only ligand-dependent activation but also activation caused by gene mutations in Wnt signaling factors
More news about: Eisai Inc.